New Clinical Trial Patent Recruitment Reports Now Available at

07 Sep 2011 • by Natalie Aster

Market Publishers Ltd informs that new GBI Research's Pharmaceutical Industry Reports have been added to its catalogue:

Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade.

The average patient recruitment per trial per year has continued to decline over the past decade across the five major indications of autoimmune disorders which are Multiple Sclerosis, Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis and Psoriasis. The average number of patients recruited for clinical trials across five major autoimmune disorders was approximately 408 in 2000. This average had declined to 74 in 2009. In between 2000 and 2009, there is an irregular trend of average patients recruited for clinical trials in five major autoimmune disorders.

Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia.

The number of clinical trials for central nervous system diseases has increased for the past few years. The major indications which have been discussed in this report are selected on the basis of patient population and the pipeline molecules for that particular indication. On the basis of these two factors, the five major indications chosen were Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression. These five major indications have the highest number of pipeline molecules, and the patient population has a high unmet need for treatment.

Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism.

Pharmaceutical companies conduct clinical trials based on factors such as promising therapeutic areas, unmet needs for a particular indication and the presence of a significant patient population. Cardiovascular diseases are an indication for which clinical trials are conducted to try and provide better treatment options. Changing lifestyles, which includes poor diets and reduced physical activity, is one of the leading causes of CVDs. The total number of ongoing cardiovascular trials was 5,165 (starting in the period between 2005 and 2010). This count includes all trials (interventional) which were started, ongoing or in the follow-up phase during this period.

Published: September’11  
Per Report Price: US$ 3,500.00 (Single User License)

More new market research reports by GBI Research can be found at GBI Research's page

To order the report or ask for sample pages contact


MarketPublishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970